Latest data

Independent journalism on peptide research, trials, and regulation. We do not sell peptides. Our editorial standards

Top StoryResearch
Exenatide (Approved)Dulaglutide (Approved)Orforglipron (Approved)LL-37 (Investigational)Kisspeptin (Investigational)Gonadorelin (Approved)Desmopressin (Approved)GHK-Cu (Unclear)

This Week in Peptide Research: GLP-1 Mechanism Studies, LL-37 Engineering Advances, and Kisspeptin's Reach Beyond Reproduction

New PubMed literature from September 6 through September 13, 2026, was a quiet week with no new phase 3 trial readout. The literature clustered into four threads: mechanistic and clinical questions about approved GLP-1 drugs, two protein-engineering advances for the antimicrobial peptide LL-37, three papers on kisspeptin's effects on cardiac development, gonadotropin release, and receptor selectivity, and a large real-world safety analysis of desmopressin use around childbirth.

Read full story

Is it legal? Check any peptide

Legal status by country, sport-legality, and cited evidence for all 56 tracked peptides

Full regulatory matrix
Are peptides legal in the US?FDA status of every tracked peptideAre peptides legal in Australia?TGA status of every tracked peptideLegal in the European Union?EMA status of every tracked peptideWhich peptides are banned in sport?WADA status of every tracked peptide

Latest News

All news
  1. Research

    Nature Study Finds Late-Life Semaglutide Extended Lifespan and Slowed Ageing Markers in Female Mice

    Researchers at the University of California, Berkeley report that semaglutide given to older female mice for three months extended their lifespan by about 100 days on average and matched or exceeded several benefits of calorie restriction, according to a study published September 2, 2026 in Nature. The authors say there is no indication similar results could be immediately achieved in humans.

    Semaglutide (Approved)
    Peptide Science Daily Staff5 min
  2. Research

    Updated Annals of Internal Medicine Review Adds Orforglipron and Amycretin Data to GLP-1 Weight-Loss Evidence

    A McGill-led team's updated systematic review of 38 randomized trials and nearly 26,000 participants finds tirzepatide and semaglutide still lead approved options, while early data on amycretin and retatrutide point to larger but less certain effects.

    Tirzepatide (Approved)Semaglutide (Approved)Liraglutide (Approved)Orforglipron (Approved)Retatrutide (Investigational)Amycretin (Investigational)Cagrilintide (Investigational)
    Peptide Science Daily Staff6 min
  3. Research

    This Week in Peptide Research: An Online-Sourced Retatrutide Safety Case, Tissue-Repair Reviews, and Mitochondrial Peptide Studies

    New PubMed literature from August 24 through August 30, 2026 was a quieter week with no new phase 3 trial data. The notable items were a clinical case report describing complications after a patient used an online-purchased product marketed as retatrutide, two papers on regenerative and antimicrobial peptides in tissue repair, two reviews on mitochondrial-derived peptides, a biomarker analysis from the completed EXSCEL trial of exenatide, and a review on bone-building peptides in athletic bone stress injuries.

    Retatrutide (Investigational)BPC-157 (Restricted / Rx-only)TB-500 (Prohibited)GHK-Cu (Unclear)LL-37 (Investigational)Humanin (Investigational)MOTS-c (Prohibited)Teriparatide (Approved)Abaloparatide (Approved)Exenatide (Approved)
    Peptide Science Daily Staff5 min
  4. News

    Large Matched-Cohort Study Finds Modest Retinopathy Risk With GLP-1 Drugs, No Significant Link to Rare Optic Nerve Disorder

    A propensity-matched cohort study of more than 98,000 patient pairs, published online August 27, 2026 in Diabetes, Obesity and Metabolism, found GLP-1 receptor agonist use associated with a modest increase in diabetic retinopathy compared with DPP-4 inhibitors, but no statistically significant increase in the rare optic nerve condition NAION.

    Semaglutide (Approved)Liraglutide (Approved)Dulaglutide (Approved)Exenatide (Approved)
    Peptide Science Daily Staff5 min
Advertise with usReach a focused audience of peptide researchers, clinicians, and industry readers.Rates & availability
  1. Research

    Large Cohort Study in JAMA Psychiatry Links GLP-1 Drugs to Lower Mortality in People With Serious Mental Illness

    A retrospective analysis of more than 1.5 million matched patients found lower all-cause mortality and fewer cardiovascular events among people who started a GLP-1 receptor agonist rather than an SGLT2 inhibitor, with the largest absolute differences in people with bipolar disorder, major depressive disorder, or schizophrenia. The study was published online August 26, 2026 in JAMA Psychiatry.

    Semaglutide (Approved)Tirzepatide (Approved)
    Peptide Science Daily Staff6 min
  2. Research

    First US-Based Trial of Mazdutide Finds Up to 18 Percent Weight Loss in Phase 2 Study Published in The Lancet Diabetes & Endocrinology

    A phase 2, placebo-controlled trial conducted at 24 US centers found once-weekly mazdutide produced dose-dependent weight loss of up to 18.1 percent over 32 weeks, the first published US population data for the GLP-1/glucagon dual agonist, which is approved in China but remains investigational in the United States.

    Mazdutide (Approved)
    Peptide Science Daily Staff4 min
  3. Research

    This Week in Peptide Research: Survodutide's Phase 3 Obesity Data, Mazdutide's US Phase 2 Trial, and a Bone-Peptide Cluster

    New PubMed literature from August 17 through August 23, 2026 included a phase 3 trial of the glucagon/GLP-1 dual agonist survodutide in obesity, a phase 2 US trial of mazdutide, a meta-analysis and a biomarker study on cagrilintide and retatrutide, a pediatric trial of dulaglutide in thalassemia-induced diabetes, three papers on bone-building peptides, a basic-science paper identifying a new antimicrobial function for the mitochondrial peptide MOTS-c, and smaller items on GHK-Cu, octreotide, and semaglutide.

    Survodutide (Investigational)Mazdutide (Approved)Cagrilintide (Investigational)Semaglutide (Approved)Retatrutide (Investigational)Dulaglutide (Approved)Teriparatide (Approved)Abaloparatide (Approved)MOTS-c (Prohibited)GHK-Cu (Unclear)Octreotide (Approved)
    Peptide Science Daily Staff6 min
  4. Research

    Full PIONEER TEENS Results Posted: Oral Semaglutide Lowered HbA1c in Adolescents With Type 2 Diabetes

    ClinicalTrials.gov posted the complete results of PIONEER TEENS on August 21, 2026, the first phase 3 trial of an oral GLP-1 therapy in children and adolescents with type 2 diabetes. The 132-participant trial found oral semaglutide reduced HbA1c more than placebo over 52 weeks. Novo Nordisk has said it plans to seek regulatory approval in this age group but oral semaglutide is not currently approved for pediatric use.

    Semaglutide (Approved)
    Peptide Science Daily Staff4 min
  7. Research

    STEP 12 Trial Finds Semaglutide Cut Bodyweight by Nearly 10 Percentage Points More Than Placebo in Chinese Adults

    A phase 3b randomized trial conducted at 19 sites in mainland China and Taiwan found once-weekly semaglutide 2.4 mg produced significantly greater weight loss than placebo, using BMI thresholds defined locally for Chinese and Taiwanese populations. The results were published August 10, 2026 in The Lancet Diabetes & Endocrinology.

    Semaglutide (Approved)
    Peptide Science Daily Staff4 min
  9. Research

    This Week in Peptide Research: A Kisspeptin Reproductive-Axis Cluster, Survodutide's Liver Mechanism, and Teriparatide's Cost Question

    New PubMed literature from August 2 through August 8, 2026 included four papers on kisspeptin and reproductive-axis signaling, a mediation analysis separating survodutide's liver effects from its weight-loss effects, a multi-drug review of GLP-1 receptor agonists in dialysis patients, a network meta-analysis and a cost-effectiveness review on the bone-building peptide teriparatide, and smaller items on a peptide-coated antibiotic nanoparticle, real-world radionuclide therapy outcomes, and a small case series on gut peptide drugs for constipation.

    Kisspeptin (Investigational)Survodutide (Investigational)Semaglutide (Approved)Liraglutide (Approved)Dulaglutide (Approved)Tirzepatide (Approved)Teriparatide (Approved)LL-37 (Investigational)Octreotide (Approved)Linaclotide (Approved)
    Peptide Science Daily Staff6 min
  10. Research

    Pooled Analysis of Three Phase 3 Trials in The Lancet Diabetes & Endocrinology Finds Semaglutide Cut Major Kidney Events by 16%

    A prespecified pooled analysis of participant-level data from the SELECT, FLOW, and SOUL randomized trials, covering more than 30,000 people, found semaglutide reduced a composite of kidney failure, major kidney function loss, and kidney- or cardiovascular-related death. The analysis was published August 7, 2026 in The Lancet Diabetes & Endocrinology.

    Semaglutide (Approved)
    Peptide Science Daily Staff5 min
  12. Research

    JAMA Publishes Companion Phase 3 Trials of Mazdutide in Obesity and Orforglipron Added to Insulin in Type 2 Diabetes

    GLORY-2 found once-weekly mazdutide produced substantially greater weight loss than placebo in Chinese adults with obesity, while ACHIEVE-5 found oral orforglipron added to titrated insulin glargine improved glycemic control in type 2 diabetes. Both randomized trials, along with an editorial comparing them, were published August 4, 2026 in JAMA.

    Mazdutide (Approved)Orforglipron (Approved)
    Peptide Science Daily Staff5 min
  13. Research

    This Week in Peptide Research: Bone-Building Peptide Mechanisms, Real-World GLP-1 Data, and a Reproductive-Axis Cluster

    New PubMed literature from July 26 through August 1, 2026 included four mechanistic and real-world studies on the bone-building peptides teriparatide and abaloparatide, real-world and post hoc data on tirzepatide and CagriSema, an animal study on orforglipron's effect on aortic aneurysm, two papers on kisspeptin and reproductive-axis signaling, and safety or detection work touching desmopressin, BPC-157, and AOD-9604.

    Teriparatide (Approved)Abaloparatide (Approved)Tirzepatide (Approved)Cagrilintide (Investigational)Orforglipron (Approved)Kisspeptin (Investigational)Desmopressin (Approved)BPC-157 (Restricted / Rx-only)AOD-9604 (Prohibited)
    Peptide Science Daily Staff6 min
  17. Research

    This Week in Peptide Research: GIP Receptor Debate, Bone-Building Peptides, and New Safety Signals

    A week of new PubMed literature brought dueling papers on activating versus blocking the GIP receptor for weight loss, fresh evidence on bone-building peptides, safety analyses touching retatrutide and weight-loss drugs generally, and a formal regulatory profile of orforglipron following its April 2026 approval.

    Cagrilintide (Investigational)Maridebart cafraglutide (Investigational)Abaloparatide (Approved)Teriparatide (Approved)Retatrutide (Investigational)Setmelanotide (Approved)Orforglipron (Approved)Humanin (Investigational)
    Peptide Science Daily Staff7 min
  18. News

    FDA Advisory Panel Recommends Six of Seven Peptides for Compounding, Rejects Emideltide

    The Pharmacy Compounding Advisory Committee voted over two days to recommend BPC-157, KPV, TB-500, MOTS-c, semax and epitalon for the Section 503A bulk drug substances list, and voted against emideltide. The votes are advisory and non-binding, and the FDA had not announced a final decision as of publication.

    BPC-157 (Restricted / Rx-only)TB-500 (Prohibited)KPV (Investigational)MOTS-c (Prohibited)Semax (Investigational)Epithalon (Investigational)DSIP (Investigational)
    Peptide Science Daily Staff6 min
  19. News

    TGA Issues Class-Wide GLP-1 Warning Over Rare Eye Disorder Linked to Semaglutide and Tirzepatide

    Australia's Therapeutic Goods Administration updated product warnings for every GLP-1 receptor agonist sold in the country after adverse-event reports linked the drugs to non-arteritic anterior ischaemic optic neuropathy, a rare condition that can cause permanent vision loss.

    Semaglutide (Approved)Tirzepatide (Approved)Liraglutide (Approved)Dulaglutide (Approved)
    Peptide Science Daily Staff5 min
  20. News

    FDA Advisory Panel Votes to Recommend Compounding of BPC-157, TB-500 and Four Other Peptides, Rejects Emideltide

    The Pharmacy Compounding Advisory Committee's two-day vote on seven nominated peptides came over the written objections of the FDA's own career scientists. The recommendations are non-binding, and none of the peptides is an FDA-approved drug.

    BPC-157 (Restricted / Rx-only)TB-500 (Prohibited)KPV (Investigational)MOTS-c (Prohibited)Semax (Investigational)Epithalon (Investigational)DSIP (Investigational)
    Peptide Science Daily Staff6 min
  27. Research

    BMJ Network Meta-Analysis Compares 19 Obesity Drugs on Weight Loss, Heart Risk, and Side Effects

    A systematic review of 262 trials and nearly 100,000 patients puts tirzepatide, semaglutide, CagriSema, orforglipron, and other peptide-based therapies side by side, and finds that larger weight loss usually comes with larger trade-offs.

    Tirzepatide (Approved)Semaglutide (Approved)Cagrilintide (Investigational)Orforglipron (Approved)Retatrutide (Investigational)Mazdutide (Approved)
    Peptide Science Daily Staff7 min
  29. News

    FDA Scientists Question Evidence for Peptides Backed by RFK Jr. Ahead of Advisory Panel

    Career reviewers at the agency posted documents finding little human evidence for BPC-157, TB-500 and five other peptides, setting up a clash with Health Secretary Robert F. Kennedy Jr., who has pushed to widen access before the July 23-24 advisory meeting.

    BPC-157 (Restricted / Rx-only)TB-500 (Prohibited)KPV (Investigational)MOTS-c (Prohibited)Semax (Investigational)Epithalon (Investigational)DSIP (Investigational)
    Peptide Science Daily Staff6 min

Live Trackers

Data aggregated from primary regulatory and trial sources

All trackers
Clinical Trials Tracker
3662Registered trials tracked

Registered interventional trials across GLP-1, tissue repair, anti-aging, and metabolic peptide categories.

Regulatory Status Tracker
56Compounds monitored

FDA, EMA, TGA, and Health Canada regulatory status for peptide therapeutics and research compounds.

Adverse Events Database
64,198FAERS reports · tracked compounds

Aggregated adverse event reports associated with peptide compounds from the FDA FAERS pharmacovigilance database.

Study of the Week

Research archive
Abstract molecular ribbon model of a metabolic peptide
New England Journal of Medicine
Semaglutide (Approved)

The SELECT Trial: Semaglutide Cut Major Cardiovascular Events by 20% in People Without Diabetes

Coverage by Peptide Science Daily Staff, Editorial Desk

Study limitations: A secondary-prevention population (older adults with established cardiovascular disease, predominantly male and white); the results do not establish benefit in people without established heart disease. Not medical advice.

Read original paper (opens in a new tab)

Explore Compounds

All compounds

The science briefing researchers actually read

Independent, citation-grounded reporting on peptide trials, regulatory decisions, and safety signals. No hype, no purchase prompts.

  • Weekly digest of peer-reviewed peptide research
  • Trial updates and recruiting notifications
  • Regulatory moves from FDA, EMA, TGA, and Health Canada

Independent publication. We do not sell or supply peptides. No spam. No purchase prompts. Unsubscribe at any time.